Cassava Sciences (NASDAQ:SAVA – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.11, Zacks reports.
Cassava Sciences Stock Performance
Cassava Sciences stock opened at $2.48 on Tuesday. The stock has a market capitalization of $119.31 million, a P/E ratio of -1.80 and a beta of -0.95. Cassava Sciences has a 52 week low of $2.23 and a 52 week high of $42.20. The stock has a fifty day moving average of $2.53 and a 200-day moving average of $15.30.
Wall Street Analyst Weigh In
Separately, HC Wainwright cut Cassava Sciences from a “buy” rating to a “neutral” rating and set a $116.00 price objective on the stock. in a report on Tuesday, November 26th.
Cassava Sciences Company Profile
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Stories
- Five stocks we like better than Cassava Sciences
- How to Calculate Stock Profit
- Monster Beverage: Monster Upside or a Risky Buy?
- How to trade using analyst ratings
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- What to Know About Investing in Penny Stocks
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
